Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 978-985

  Forde, Éanna ^a,b   Humphreys, Hilary ^b,c   Greene, Catherine M ^c   Fitzgerald Hughes, Deirdre ^b   Devocelle, Marc ^a  

^a University College Dublin   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HOST DEFENSE PEPTIDE; LEUKOCYTE ELASTASE; PEPTIDE AAG BAC8C; PEPTIDE AAG P18; PEPTIDE AG HB43; PEPTIDE BAC8C; PEPTIDE HB43; PEPTIDE P18; PEPTIDE PRO HB43; PEPTIDE PRO P18; PEPTIDE PRO-BAC8C; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROSIS; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ALPHA-DEFENSINS; AMINO ACID SEQUENCE; BRONCHOALVEOLAR LAVAGE FLUID; COCULTURE TECHNIQUES; CYSTIC FIBROSIS; HUMANS; LEUKOCYTE ELASTASE; LUNG; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PRIMARY CELL CULTURE; PRODRUGS; PSEUDOMONAS AERUGINOSA; SODIUM CHLORIDE;

EID: 84893519181     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01167-13     Document Type: Article

References (54)

1. Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951. http://dx.doi.org/10.1164/rccm.200304-505SO.
2. Callaghan M, McClean S. 2012. Bacterial host interactions in cystic fibrosis. Curr. Opin. Microbiol. 15:71-77. http://dx.doi.org/10.1016/j.mib.2011. 11.001.
3. Maiz L, Giron RM, Olveira C, Quintana E, Lamas A, Pastor D, Canton R, Mensa J. 16 April 2013. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin. Pharmacother. http://dx.doi.org/10.1517/14656566.2013.790366.
4. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, Regelmann W. 2012. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J. Cyst. Fibros. 11:293-299. http://dx.doi.org/10.1016/j.jcf.2012.02.005.
5. Jain K, Smyth AR. 2012. Current dilemmas in antimicrobial therapy in cystic fibrosis. Expert Rev. Respir. Med. 6:407-422. http://dx.doi.org/10.1586/ ers.12.39.
6. Greally P, Whitaker P, Peckham D. 2012. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Med. Res. Opin. 28:1059-1067. http://dx.doi.org/10.1185/ 03007995.2012.674500.
7. Kelly E, Greene CM, McElvaney NG. 2008. Targeting neutrophil elastase in cystic fibrosis. Expert Opin. Ther. Targets 12:145-157. http://dx.doi.org/10. 1517/14728222.12.2.145.
8. Voynow JA, Fischer BM, Zheng S. 2008. Proteases and cystic fibrosis. Int. J. Biochem. Cell Biol. 40:1238-1245. http://dx.doi.org/10.1016/j.biocel.2008. 03.003.
9. Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG. 2011. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J. Biol. Chem. 286:7692-7704. http://dx.doi.org/10.1074/jbc.M110.183863.
10. Rees DD, Brain JD, Wohl ME, Humes JL, Mumford RA. 1997. Inhibition of neutrophil elastase in CF sputum by L-658,758. J. Pharmacol. Exp. Ther. 283:1201-1206.
11. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. http://dx.doi.org/10.1038/nbt1267.
12. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a.
13. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. 2002. Translocating proline-rich peptides from the antimicrobial peptide bactenecin. Biochemistry 41:14150-14157. http://dx.doi.org/10.1021/bi026661l.
14. Westerhoff HV, Juretić D, Hendler RW, Zasloff M. 1989. Magainins and the disruption of membrane-linked free-energy transduction. Proc. Natl. Acad. Sci. U. S. A. 86:6597-6601. http://dx.doi.org/10.1073/pnas.86.17.6597.
15. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Invest. 101:178-187. http://dx.doi.org/10.1172/JCI562.
16. Fjell CD, Hiss JA, Hancock RE, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11:37-51. http://dx.doi.org/10.1038/nrd3591.
17. Devocelle M. 2012. Targeted antimicrobial peptides. Front. Immunol. 3:309. http://dx.doi.org/10.3389/fimmu.2012.00309.
18. Fitzgerald-Hughes D, Devocelle M, Humphreys H. 2012. Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. FEMS Immunol. Med. Microbiol. 65:399-412. http://dx.doi.org/10.1111/j.1574-695X.2012.00954.x.
19. Giuliani A, Pirri G, Nicoletto S. 2007. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2:1-33. http://dx.doi.org/10.2478/s11535-007-0010-5.
20. Steinstraesser L, Kraneburg UM, Hirsch T, Kesting M, Steinau HU, Jacobsen F, Al-Benna S. 2009. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci. 10:3951-3970. http://dx.doi.org/10.3390/ijms10093951.
21. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. 2012. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 11:461-479. http://dx.doi.org/10.1016/j.jcf. 2012.10.004.
22. Arnusch CJ, Pieters RJ, Breukink E. 2012. Enhanced membrane pore formation through high-affinity targeted antimicrobial peptides. PLoS One 7:e39768. http://dx.doi.org/10.1371/journal.pone.0039768.
23. Eckert R, He J, Yarbrough DK, Qi F, Anderson MH, Shi W. 2006. Targeted killing of Streptococcus mutans by a pheromone-guided "smart" antimicrobial peptide. Antimicrob. Agents Chemother. 50:3651-3657. http://dx.doi.org/10.1128/AAC.00622-06.
24. Franzman MR, Burnell KK, Dehkordi-Vakil FH, Guthmiller JM, Dawson DV, Brogden KA. 2009. Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int. J. Antimicrob. Agents 33:14-20. http://dx.doi.org/10.1016/j.ijantimicag.2008.05. 021.
25. Desgranges S, Le Prieult F, Daly A, Lydon J, Brennan M, Rai DK, Subasinghage AP, Hewage CM, Cryan SA, Greene C, McElvaney NG, Smyth TP, Fitzgerald-Hughes D, Humphreys H, Devocelle M. 2011. In vitro activities of synthetic host defense propeptides processed by neutrophil elastase against cystic fibrosis pathogens. Antimicrob. Agents Chemother. 55:2487-2489. http://dx.doi.org/10.1128/AAC.01384-10.
26. Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927. http://dx.doi.org/10.1128/AAC.49.7.2921-2927.2005.
27. Weiner DJ, Bucki R, Janmey PA. 2003. The antimicrobial activity of the cathelicidin LL-37 is inhibited by F-actin bundles and restored by gelsolin. Am. J. Respir. Cell Mol. Biol. 28:738-745. http://dx.doi.org/10.1165/rcmb.2002- 0191OC.
28. Bucki R, Byfield FJ, Janmey PA. 2007. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur. Respir. J. 29:624-632. http://dx.doi.org/10.1183/09031936.00080806.
29. Felgentreff K, Beisswenger C, Griese M, Gulder T, Bringmann G, BAL fluids R. 2006. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 27:3100-3106. http://dx.doi.org/10.1016/j.peptides.2006.07.018.
30. Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. 2005. Glycosaminoglycans inhibit the antibacterial action of LL-37 in biological fluids. J. Investig. Dermatol. 125:A70-A70. http://dx.doi.org/10.1093/jac/ dki460.
31. Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, Greally P, Murphy P, O'Neill SJ, McElvaney NG. 2009. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 183:543-551. http://dx.doi.org/10.4049/jimmunol.0803959.
32. Hilpert K, Volkmer-Engert R, Walter T, Hancock REW. 2005. Highthroughput generation of small antibacterial peptides with improved activity. Nat. Biotech. 23:1008-1012. http://dx.doi.org/10.1038/nbt1113.
33. Shin SY, Kang JH, Hahm KS. 1999. Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides. J. Pept. Res. 53:82-90. http://dx.doi.org/10.1111/j. 1399-3011.1999.tb01620.x.
34. CLSI. 2010. Performance standards for antimicrobial susceptibility testing, 20th informational supplement, vol M100-S12. Clinical and Laboratory Standards Institute, Wayne, PA.
35. WuM, Hancock RE. 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 274:29-35. http://dx.doi.org/10.1074/jbc.274.1.29.
36. Livermore DM. 2009. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64(Suppl 1):i29-36. http://dx.doi.org/10.1093/jac/dkp255.
37. Septimus EJ, Kuper KM. 2009. Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century. Clin. Pharmacol. Ther. 86:336-339. http://dx.doi.org/10.1038/clpt.2009.122.
38. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76:4176-4182. http://dx.doi.org/10.1128/IAI.00318-08.
39. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, McElvaney NG. 2005. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J. Immunol. 174: 1638-1646.
40. Barańska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. 2006. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J. Antimicrob. Chemother. 57:260-265. http://dx.doi.org/10.1093/jac/ dki460.
41. Kellett F, Robert NM. 2011. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 105:1831-1835. http://dx.doi.org/10.1016/j.rmed.2011.07.019.
42. Shin SY, Yang ST, Park EJ, Eom SH, Song WK, Kim Y, Hahm KS, Kim JI. 2002. Salt resistance and synergistic effect with vancomycin of alphahelical antimicrobial peptide P18. Biochem. Biophys. Res. Commun. 290: 558-562. http://dx.doi.org/10.1006/bbrc.2001.6234.
43. Mai J, Tian XL, Gallant JW, Merkley N, Biswas Z, Syvitski R, Douglas SE, Ling J, Li YH. 2011. A novel target-specific, salt-resistant antimicrobial peptide against the cariogenic pathogen Streptococcus mutans. Antimicrob. Agents Chemother. 55:5205-5213. http://dx.doi.org/10.1128/AAC.05175-11.
44. Scudiero O, Galdiero S, Nigro E, Del Vecchio L, Di Noto R, Cantisani M, Colavita I, Galdiero M, Cassiman JJ, Daniele A, Pedone C, Salvatore F. 2013. Chimeric beta-defensin analogs, including the novel 3NI analog, display salt-resistant antimicrobial activity and lack toxicity in human epithelial cell lines. Antimicrob. Agents Chemother. 57:1701-1708. http://dx.doi.org/10.1128/ AAC.00934-12.
45. Wang J, Wong ES, Whitley JC, Li J, Stringer JM, Short KR, Renfree MB, Belov K, Cocks BG. 2011. Ancient antimicrobial peptides kill antibioticresistant pathogens: Australian mammals provide new options. PLoS One 6:e24030. http://dx.doi.org/10.1371/journal.pone.0024030.
46. Scott MG, Yan H, Hancock RE. 1999. Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect. Immun. 67:2005-2009.
47. Jacobsen F, Mohammadi-Tabrisi A, Hirsch T, Mittler D, Mygind PH, Sonksen CP, Raventos D, Kristensen HH, Gatermann S, Lehnhardt M, Daigeler A, Steinau HU, Steinstraesser L. 2007. Antimicrobial activity of the recombinant designer host defence peptide P-novispirin GIO in infected full-thickness wounds of porcine skin. J. Antimicrob. Chemother. 59:493-498. http://dx.doi.org/10.1093/jac/ dkl513.
48. Scudiero O, Galdiero S, Cantisani M, Di Noto R, Vitiello M, Galdiero M, Naclerio G, Cassiman JJ, Pedone C, Castaldo G, Salvatore F. 2010. Novel synthetic, salt-resistant analogs of human betadefensins 1 and 3 endowed with enhanced antimicrobial activity. Antimicrob. Agents Chemother. 54:2312-2322. http://dx.doi.org/10.1128/AAC.01550-09.
49. Deslouches B, Steckbeck JD, Craigo JK, Doi Y, Mietzner TA, Montelaro RC. 2013. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob. Agents Chemother. 57:2511-2521. http://dx.doi.org/10.1128/AAC.02218-12.
50. Desgranges S, Ruddle CC, Burke LP, McFadden TM, O'Brien JE, Fitzgerald-Hughes D, Humphreys H, Smyth TP, Devocelle M. 2012. A-Lactam-host defence peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. RSC Adv. 2:2480-2492. http://dx.doi.org/10.1039/c2ra01351g.
51. Strömstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M. 2009. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob. Agents Chemother. 53:593-602. http://dx.doi.org/10.1128/AAC.00477-08.
52. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M. 1990. All-Dmagainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274:151-155. http://dx.doi.org/10.1016/0014-5793(90)81351-N.
53. Hong SY, Oh JE, Lee KH. 1999. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem. Pharmacol. 58:1775-1780. http://dx.doi.org/10.1016/S0006-2952(99) 00259-2.
54. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. 2013. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibros. 12:29-34. http://dx.doi.org/10.1016/j.jcf.2012.06.001.